Kamakura Techno‒Science, Inc. is a spin-off contract research organization(CRO) from Toray Industries’ research institution.
They are a GLP-compliant facility, the company conducts a wide range of non-clinical studies—Pharmacology(PD), Safety, and Pharmacokinetics(PK)studies—at their facilities.
The company offers non-clinical pharmacological studies, which cover diverse disease areas. This includes Neurological, Cardiovascular, and Gastrointestinal related areas (Cerebral infarction, Diabetes, and Allergic dermatitis models). They use evaluation methods established through Toray Industries’expertise in pharmaceutical research.
Kamakura Techno‒Science, Inc. Science also provides numerous exploratory and PoC-supporting models, including L-DOPA–induced model and Pruritus model. You can expect their flexible and scientifically backed proposal for your non-clinical needs.
KamakuraTechno‒Science provides non-clinical safety testing for a wide range of material, including pharmaceutical drugs, medical devices, or food additives.
The company is in compliance with GLP standards—Pharmaceutical GLP, Medical Device GLP, Chemical Substances Control Law GLP, and OECD GLP. —They offer extensive experience in general toxicity, genotoxicity, immunotoxicity, and biological safety testing.
Its capabilities also include skin sensitization/irritation testing, pyrogen testing, and other assessments required in the medical device development, delivering both regulatory compliance and high reliability.
Using high-sensitivity LC/MS/MS platforms such as the SCIEX QTRAP® 6500, Kamakura Techno‒Science, Inc. performs high-precision drug concentration analysis for various biological materials.
The company supports both in-vitro and in-vivo pharmacokinetic assessments, including CYP inhibition/induction studies, metabolic stability studies, PK studies, and biliary excretion studies.
In addition to GLP-compliant analysis, metabolite profiling and hemodialysis removal assessment are also available.
These high-quality, radioisotope-free data support accurate evaluation of drug’s safety and efficacy.
The Chung model reproduces neuropathic pain caused by peripheral nerve injury and is widely used in evaluating analgesic drug candidates.
By ligating a portion of the sciatic nerve, mechanical allodynia and thermal hypersensitivity can be quantitatively assessed in the affected hindlimb.
Kamakura Techno-Science maintains multiple neurological disease models—including the Chung model, water-immersion stress model, and tremor model. They offer GLP-compliant testing to deliver highly reliable data.
Reference:
https://www.kamakura-ts.co.jp/test/pharmacology/index.html
The company conducts pharmacological evaluations in respiratory disease research using a well-established pulmonary fibrosis model.
Fibrosis is induced by repeated administration of bleomycin, enabling quantitative assessment of anti-fibrotic drug efficacy.
Study endpoints include lung function, histopathology, and inflammatory markers, providing comprehensive multi-angle evaluation.
GLP-compliant execution is also available, supporting clients’ drug development with reliable and reproducible data.
Reference:
https://www.kamakura-ts.co.jp/test/pharmacology/index.html
| Address | 6-10-1 Tebiro, Kamakura, Kanagawa, Japan (Toray Industries Basic Research Center) |
|---|---|
| Tel | +81-467-32-9775 |
| Website | https://www.kamakura-ts.co.jp/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.